trending Market Intelligence /marketintelligence/en/news-insights/trending/2qidh563zhdcn7djxbskng2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Minerva Neurosciences appoints chief medical officer

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Minerva Neurosciences appoints chief medical officer

Minerva Neurosciences Inc. appointed Michael Davidson chief medical officer, to lead strategic development and clinical advancement of the company's products for schizophrenia, insomnia, major depressive disorder and Parkinson's disease.

Davidson is professor of psychiatry at the Sackler School of Medicine, Tel Aviv University, and has worked as a consultant for Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Roche Holding Ltd., Novartis AG, Eli Lilly & Co., BioLineRx Ltd. and Takeda Pharmaceutical Co. Ltd., among others.